View Item 

Show simple item record

Efficacy of biologics for the treatment of periodontal infrabony defects: An American Academy of Periodontology best evidence systematic review and network meta-analysis
dc.contributor.authorTavelli, Lorenzo
dc.contributor.authorChen, Chia-Yu (jennifer)
dc.contributor.authorBarootchi, Shayan
dc.contributor.authorKim, David M.
dc.date.accessioned2023-01-11T16:23:22Z
dc.date.available2024-01-11 11:23:20en
dc.date.available2023-01-11T16:23:22Z
dc.date.issued2022-12
dc.identifier.citationTavelli, Lorenzo; Chen, Chia-Yu (jennifer) ; Barootchi, Shayan; Kim, David M. (2022). "Efficacy of biologics for the treatment of periodontal infrabony defects: An American Academy of Periodontology best evidence systematic review and network meta- analysis." Journal of Periodontology 93(12): 1803-1826.
dc.identifier.issn0022-3492
dc.identifier.issn1943-3670
dc.identifier.urihttps://hdl.handle.net/2027.42/175435
dc.description.abstractBackgroundA large variety of biomaterials, biologics and membranes have been utilized in the past 40 years for the regenerative treatment of periodontal infrabony defects. Biologic agents have progressively gained popularity among clinicians and are routinely used for periodontal regeneration. In alignment with the goals of the American Academy of Periodontology (AAP) Best Evidence Consensus (BEC) on the use of biologic mediators in contemporary clinical practice, the aim of this sytematic review was to evaluate the effect of biologic agents, specifically autogenous blood-dervied products (ABPs), enamel matrix derivative (EMD) and recombinant human platelet-derived growth factor-BB (rhPDGF-BB), on the regenerative outcomes of infrabony defects.MethodsA detailed systematic search was conducted to identify eligible randomized control trials (RCTs) reporting the outcomes of periodontal regenerative therapy using biologics for the treatment of infrabony defects. A frequentist mixed-modeling approach to network meta-analysis (NMA), characterized by the assessment of three individual components for the treatment of an infrabony defect (the bone graft material [BG], the biologic agent, the application of a barrier membrane) was performed to evaluate and compare the relative efficacy of the different components, on the outcomes of different therapeutic modalities of periodontal regeneration.ResultsA total of 153 eligible RCTs were included, with 150 studies contributing to the NMA. The quantitative analysis showed that the addition of biologic agents to bone graft significantly improves the clinical and radiographic outcomes, as compared to BG and flap procedures alone. Barrier membranes enhanced the regenerative outcomes of BG but did not provide further benefits in combination with biologics. The type of BG (autogenous, allogeneic, xenogeneic or alloplastic) and the biologic agent (EMD, platelet-rich fibrin [PRF], platelet-rich plasma [PRP] or rhPDGF-BB) played a significant role on the final outcomes of infrabony defects. Allogeneic and xenogeneic BGs exhibited statistically significantly superior clinical gain than synthetic and autogenous BGs (p < 0.05 in all the comparisons), while rhPDGF-BB and PRF demonstrated significantly higher stability of the gingival margin (p < 0.01) and radiographic bone fill/gain (p < 0.05), together with greater, although not statistically significant, clinical attachment level gain and pocket depth reduction, than EMD and PRP. Overall, rhPDGF-BB exhibited the largest effect size for most parameters, including clinical attachment level gain, pocket depth reduction, less gingival recession and radiographic linear bone gain. Considering the relatively high number of trials presenting an unclear or high risk of bias, the strength of recommendation supporting the use of PRP was judged weak, while the recommendation for EMD, PRF and rhPDGF-BB was deemed in favor.ConclusionsBiologics enhance the outcomes of periodontal regenerative therapy. Combination therapies involving BGs + biologics or BGs + barrier membrane demonstrated to be superior to monotherapies. The choice of the type of BG and biologic agent seems to have significant impact on the clinical and radiographic outcomes of infrabony defects.
dc.publisherCochrane
dc.publisherWiley Periodicals, Inc.
dc.subject.othergingival recession
dc.subject.othergrowth factors
dc.subject.otherinfrabony defects
dc.subject.otherperiodontal regeneration
dc.subject.otherbone grafts
dc.titleEfficacy of biologics for the treatment of periodontal infrabony defects: An American Academy of Periodontology best evidence systematic review and network meta-analysis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDentistry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175435/1/jper10959.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175435/2/jper10959_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175435/3/jper10959-sup-0001-SuppMat.pdf
dc.identifier.doi10.1002/JPER.22-0120
dc.identifier.sourceJournal of Periodontology
dc.identifier.citedreferencePradeep AR, Rao NS, Agarwal E, Bajaj P, Kumari M, Naik SB. Comparative evaluation of autologous platelet-rich fibrin and platelet-rich plasma in the treatment of 3-wall intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2012; 83: 1499 - 1507.
dc.identifier.citedreferenceZucchelli G, Amore C, Montebugnoli L, De Sanctis M. Enamel matrix proteins and bovine porous bone mineral in the treatment of intrabony defects: a comparative controlled clinical trial. J Periodontol. 2003; 74: 1725 - 1735.
dc.identifier.citedreferenceZucchelli G, Bernardi F, Montebugnoli L, De SM. Enamel matrix proteins and guided tissue regeneration with titanium-reinforced expanded polytetrafluoroethylene membranes in the treatment of infrabony defects: a comparative controlled clinical trial. J Periodontol. 2002; 73: 3 - 12.
dc.identifier.citedreferenceH Garcia-. Network meta-analysis, a new statistical technique at urologists’ disposal to improve decision making. Int Braz J Urol. 2018; 44: 422 - 428.
dc.identifier.citedreferenceTonin FS, Rotta I, Mendes AM, Pontarolo R. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada). 2017; 15: 943.
dc.identifier.citedreferenceBagg MK, Salanti G, McAuley JH. Comparing interventions with network meta-analysis. J Physiother. 2018; 64: 128 - 132.
dc.identifier.citedreferenceVenezia E, Goldstein M, Boyan BD, Schwartz Z. The use of enamel matrix derivative in the treatment of periodontal defects: a literature review and meta-analysis. Crit Rev Oral Biol Med. 2004; 15: 382 - 402.
dc.identifier.citedreferenceLyngstadaas SP, Lundberg E, Ekdahl H, Andersson C, Gestrelius S. Autocrine growth factors in human periodontal ligament cells cultured on enamel matrix derivative. J Clin Periodontol. 2001; 28: 181 - 188.
dc.identifier.citedreferenceLynch SE, Williams RC, Polson AM, et al. A combination of platelet-derived and insulin-like growth factors enhances periodontal regeneration. J Clin Periodontol. 1989; 16: 545 - 548.
dc.identifier.citedreferenceSimion M, Rocchietta I, Kim D, Nevins M, Fiorellini J. Vertical ridge augmentation by means of deproteinized bovine bone block and recombinant human platelet-derived growth factor-BB: a histologic study in a dog model. Int J Periodontics Restorative Dent. 2006; 26: 415 - 423.
dc.identifier.citedreferenceCamelo M, Nevins ML, Schenk RK, Lynch SE, Nevins M. Periodontal regeneration in human Class II furcations using purified recombinant human platelet-derived growth factor-BB (rhPDGF-BB) with bone allograft. Int J Periodontics Restorative Dent. 2003; 23: 213 - 225.
dc.identifier.citedreferenceOneto P, Zubiry PR, Schattner M, Etulain J. Anticoagulants interfere with the angiogenic and regenerative responses mediated by platelets. Front Bioeng Biotechnol. 2020; 8: 223.
dc.identifier.citedreferenceKobayashi E, Fluckiger L, Fujioka-Kobayashi M, et al. Comparative release of growth factors from PRP, PRF, and advanced-PRF. Clin Oral Investig. 2016; 20: 2353 - 2360.
dc.identifier.citedreferenceFujioka-Kobayashi M, Miron RJ, Hernandez M, Kandalam U, Zhang Y, Choukroun J. Optimized Platelet-Rich Fibrin With the Low-Speed Concept: growth Factor Release, Biocompatibility, and Cellular Response. J Periodontol. 2017; 88: 112 - 121.
dc.identifier.citedreferenceSteed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg. 2006; 117: 143S - 149S. discussion 150S−151S.
dc.identifier.citedreferenceCheng B, Liu HW, Fu XB, Sun TZ, Sheng ZY. Recombinant human platelet-derived growth factor enhanced dermal wound healing by a pathway involving ERK and c-fos in diabetic rats. J Dermatol Sci. 2007; 45: 193 - 201.
dc.identifier.citedreferenceKaltalioglu K, Coskun-Cevher S. A bioactive molecule in a complex wound healing process: platelet-derived growth factor. Int J Dermatol. 2015; 54: 972 - 977.
dc.identifier.citedreferenceNasirzade J, Kargarpour Z, Hasannia S, Strauss FJ, Gruber R. Platelet-rich fibrin elicits an anti-inflammatory response in macrophages in vitro. J Periodontol. 2020; 91: 244 - 252.
dc.identifier.citedreferenceZhang J, Yin C, Zhao Q, et al. Anti-inflammation effects of injectable platelet-rich fibrin via macrophages and dendritic cells. J Biomed Mater Res A. 2020; 108: 61 - 68.
dc.identifier.citedreferenceReynolds MA, Kao RT, Camargo PM, et al. Periodontal regeneration – intrabony defects: a consensus report from the AAP Regeneration Workshop. J Periodontol. 2015; 86: S105 - 107.
dc.identifier.citedreferenceTroiano G, Laino L, Zhurakivska K, Cicciu M, Lo Muzio L, Lo Russo L. Addition of enamel matrix derivatives to bone substitutes for the treatment of intrabony defects: a systematic review, meta-analysis and trial sequential analysis. J Clin Periodontol. 2017; 44: 729 - 738.
dc.identifier.citedreferenceTu YK, Woolston A. Do bone grafts or barrier membranes provide additional treatment effects for infrabony lesions treated with enamel matrix derivatives? A network meta-analysis of randomized-controlled trials. J Clin Periodontol. 2010; 37: 59 - 79.
dc.identifier.citedreferenceTu YK, Needleman I, Chambrone L, Lu HK, Faggion CM. A Bayesian network meta-analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapies. J Clin Periodontol. 2012; 39: 303 - 314.
dc.identifier.citedreferenceDel Fabbro M, Karanxha L, Panda S, et al. Autologous platelet concentrates for treating periodontal infrabony defects. Cochrane Database Syst Rev. 2018; 11: CD011423.
dc.identifier.citedreferenceGraziani F, Gennai S, Petrini M, Bettini L, Tonetti M. Enamel matrix derivative stabilizes blood clot and improves clinical healing in deep pockets after flapless periodontal therapy: a Randomized Clinical Trial. J Clin Periodontol. 2019; 46: 231 - 240.
dc.identifier.citedreferenceOkuda K, Momose M, Miyazaki A, et al. Enamel matrix derivative in the treatment of human intrabony osseous defects. J Periodontol. 2000; 71: 1821 - 1828.
dc.identifier.citedreferenceEke PI, Dye BA, Wei L, et al. Update on prevalence of periodontitis in adults in the United States: nHANES 2009 to 2012. J Periodontol. 2015; 86: 611 - 622.
dc.identifier.citedreferenceEke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ. Cdc Periodontal Disease Surveillance workgroup: james Beck GDRP. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res. 2012; 91: 914 - 920.
dc.identifier.citedreferenceWong LB, Yap AU, Allen PF. Periodontal disease and quality of life: umbrella review of systematic reviews. J Periodontal Res. 2021; 56: 1 - 17.
dc.identifier.citedreferenceNyman S, Lindhe J, Karring T, Rylander H. New attachment following surgical treatment of human periodontal disease. J Clin Periodontol. 1982; 9: 290 - 296.
dc.identifier.citedreferenceAslan S, Buduneli N, Cortellini P. Entire Papilla Preservation Technique: a Novel Surgical Approach for Regenerative Treatment of Deep and Wide Intrabony Defects. Int J Periodontics Restorative Dent. 2017; 37: 227 - 233.
dc.identifier.citedreferenceCortellini P, Prato GP, Tonetti MS. The simplified papilla preservation flap. A novel surgical approach for the management of soft tissues in regenerative procedures. Int J Periodontics Restorative Dent. 1999; 19: 589 - 599.
dc.identifier.citedreferenceCortellini P, Prato GP, Tonetti MS. The modified papilla preservation technique. A new surgical approach for interproximal regenerative procedures. J Periodontol. 1995; 66: 261 - 266.
dc.identifier.citedreferenceRasperini G, Tavelli L, Barootchi S, et al. Interproximal attachment gain: the challenge of periodontal regeneration. J Periodontol. 2021; 92: 931 - 946.
dc.identifier.citedreferencePagni G, Tavelli L, Rasperini G. The Evolution of Surgical Techniques and Biomaterials for Periodontal Regeneration. Dent Clin North Am. 2022; 66: 75 - 85.
dc.identifier.citedreferenceCortellini P, Tonetti MS. Focus on intrabony defects: guided tissue regeneration. Periodontol 2000. 2000; 22: 104 - 132.
dc.identifier.citedreferenceCortellini P, Tonetti MS. Clinical concepts for regenerative therapy in intrabony defects. Periodontol 2000. 2015; 68: 282 - 307.
dc.identifier.citedreferenceZucchelli G, Bernardi F, Montebugnoli L, De Sanctis M. Enamel matrix proteins and guided tissue regeneration with titanium-reinforced expanded polytetrafluoroethylenemembranes in the treatment of infrabony defects: a comparative controlled clinical trial. J Periodontol. 2002; 73: 3 - 12.
dc.identifier.citedreferenceSanz M, Tonetti MS, Zabalegui I, et al. Treatment of intrabony defects with enamel matrix proteins or barrier membranes: results from a multicenter practice-based clinical trial. J Periodontol. 2004; 75: 726 - 733.
dc.identifier.citedreferencePagni G, Kaigler D, Rasperini G, Avila-Ortiz G, Bartel R, Giannobile WV. Bone repair cells for craniofacial regeneration. Adv Drug Deliv Rev. 2012; 64: 1310 - 1319.
dc.identifier.citedreferencePanda S, Khijmatgar S, Das M, Arbildo-Vega H, Del Fabbro M. Recombinant Human Derived Growth and Differentiating Factors in treatment of periodontal intrabony defects: systematic review and network meta-analysis. J Tissue Eng Regen Med. 2021; 15: 900 - 914.
dc.identifier.citedreferenceKao RT, Nares S, Reynolds MA. Periodontal regeneration – intrabony defects: a systematic review from the AAP Regeneration Workshop. J Periodontol. 2015; 86: S77 - 104.
dc.identifier.citedreferenceNevins M, Giannobile WV, McGuire MK, et al. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J Periodontol. 2005; 76: 2205 - 2215.
dc.identifier.citedreferenceTonetti MS, Lang NP, Cortellini P, et al. Enamel matrix proteins in the regenerative therapy of deep intrabony defects. J Clin Periodontol. 2002; 29: 317 - 325.
dc.identifier.citedreferencePaolantonio M, Di Tullio M, Giraudi M, et al. Periodontal regeneration by leukocyte and platelet-rich fibrin with autogenous bone graft versus enamel matrix derivative with autogenous bone graft in the treatment of periodontal intrabony defects: a randomized non-inferiority trial. J Periodontol. 2020; 91: 1595 - 1608.
dc.identifier.citedreferenceTavelli L, McGuire MK, Zucchelli G, et al. Biologics-based regenerative technologies for periodontal soft tissue engineering. J Periodontol. 2020; 91: 147 - 154.
dc.identifier.citedreferenceCastro AB, Meschi N, Temmerman A, et al. Regenerative potential of leucocyte- and platelet-rich fibrin. Part A: intra-bony defects, furcation defects and periodontal plastic surgery. A systematic review and meta-analysis. J Clin Periodontol. 2017; 44: 67 - 82.
dc.identifier.citedreferenceCastro AB, Meschi N, Temmerman A, et al. Regenerative potential of leucocyte- and platelet-rich fibrin. Part B: sinus floor elevation, alveolar ridge preservation and implant therapy. A systematic review. J Clin Periodontol. 2017; 44: 225 - 234.
dc.identifier.citedreferenceHeijl L. Periodontal regeneration with enamel matrix derivative in one human experimental defect. A case report. J Clin Periodontol. 1997; 24: 693 - 696.
dc.identifier.citedreferenceZetterstrom O, Andersson C, Eriksson L, et al. Clinical safety of enamel matrix derivative (EMDOGAIN) in the treatment of periodontal defects. J Clin Periodontol. 1997; 24: 697 - 704.
dc.identifier.citedreferenceLindskog S, Hammarstrom L. Formation of intermediate cementum. III: 3H-tryptophan and 3H-proline uptake into the epithelial root sheath of Hertwig in vitro. J Craniofac Genet Dev Biol. 1982; 2: 171 - 177.
dc.identifier.citedreferenceSlavkin HC, Bessem C, Fincham AG, et al. Human and mouse cementum proteins immunologically related to enamel proteins. Biochim Biophys Acta. 1989; 991: 12 - 18.
dc.identifier.citedreferenceMiron RJ, Sculean A, Cochran DL, et al. Twenty years of enamel matrix derivative: the past, the present and the future. J Clin Periodontol. 2016; 43: 668 - 683.
dc.identifier.citedreferenceHoang AM, Oates TW, Cochran DL. In vitro wound healing responses to enamel matrix derivative. J Periodontol. 2000; 71: 1270 - 1277.
dc.identifier.citedreferenceYoneda S, Itoh D, Kuroda S, et al. The effects of enamel matrix derivative (EMD) on osteoblastic cells in culture and bone regeneration in a rat skull defect. J Periodontal Res. 2003; 38: 333 - 342.
dc.identifier.citedreferenceTavelli L, Ravida A, Barootchi S, Chambrone L, Giannobile WV. Recombinant Human Platelet-Derived Growth Factor: a Systematic Review of Clinical Findings in Oral Regenerative Procedures. JDR Clin Trans Res. 2020: 2380084420921353.
dc.identifier.citedreferenceBoyan LA, Bhargava G, Nishimura F, Orman R, Price R, Terranova VP. Mitogenic and chemotactic responses of human periodontal ligament cells to the different isoforms of platelet-derived growth factor. J Dent Res. 1994; 73: 1593 - 1600.
dc.identifier.citedreferenceWeinberg MA, Eskow RN. Osseous defects: proper terminology revisited. J Periodontol. 2000; 71: 1928.
dc.identifier.citedreferenceNibali L, Sultan D, Arena C, Pelekos G, Lin GH, Tonetti M. Periodontal infrabony defects: systematic review of healing by defect morphology following regenerative surgery. J Clin Periodontol. 2021; 48: 100 - 113.
dc.identifier.citedreferenceHiggins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane; 2021. Available from: www.training.cochrane.org/handbook
dc.identifier.citedreferencePage MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021; 134: 178 - 189.
dc.identifier.citedreferenceHutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162: 777 - 784.
dc.identifier.citedreferenceShamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350: g7647.
dc.identifier.citedreferenceStillwell SB, Fineout-Overholt E, Melnyk BM, Williamson KM. Evidence-based practice, step by step: asking the clinical question: a key step in evidence-based practice. Am J Nurs. 2010; 110: 58 - 61.
dc.identifier.citedreferenceWachtel H, Schenk G, Böhm S, Weng D, Zuhr O, Hürzeler MB. Microsurgical access flap and enamel matrix derivative for the treatment of periodontal intrabony defects: a controlled clinical study. J Clin Periodontol. 2003; 30: 496 - 504.
dc.identifier.citedreferenceAimetti M, Fratini A, Manavella V, et al. Pocket resolution in regenerative treatment of intrabony defects with papilla preservation techniques: a systematic review and meta-analysis of randomized clinical trials. J Clin Periodontol. 2021; 48: 843 - 858.
dc.identifier.citedreferenceBarbato L, Selvaggi F, Kalemaj Z, et al. Clinical efficacy of minimally invasive surgical (MIS) and non-surgical (MINST) treatments of periodontal intra-bony defect. A systematic review and network meta-analysis of RCT’s. Clin Oral Investig. 2020; 24: 1125 - 1135.
dc.identifier.citedreferenceClementini M, Ambrosi A, Cicciarelli V, De Risi V, de Sanctis M. Clinical performance of minimally invasive periodontal surgery in the treatment of infrabony defects: systematic review and meta-analysis. J Clin Periodontol. 2019; 46: 1236 - 1253.
dc.identifier.citedreferenceMiron RJ, Moraschini V, Fujioka-Kobayashi M, et al. Use of platelet-rich fibrin for the treatment of periodontal intrabony defects: a systematic review and meta-analysis. Clin Oral Investig. 2021; 25: 2461 - 2478.
dc.identifier.citedreferenceNibali L, Koidou VP, Nieri M, Barbato L, Pagliaro U, Cairo F. Regenerative surgery versus access flap for the treatment of intra-bony periodontal defects: a systematic review and meta-analysis. J Clin Periodontol. 2020; 47 Suppl( 22 ): 320 - 351.
dc.identifier.citedreferenceStavropoulos A, Bertl K, Spineli LM, Sculean A, Cortellini P, Tonetti M. Medium- and long-term clinical benefits of periodontal regenerative/reconstructive procedures in intrabony defects: systematic review and network meta-analysis of randomized controlled clinical studies. J Clin Periodontol. 2021; 48: 410 - 430.
dc.identifier.citedreferenceTarallo F, Mancini L, Pitzurra L, Bizzarro S, Tepedino M, Marchetti E. Use of Platelet-Rich Fibrin in the Treatment of Grade 2 Furcation Defects: systematic Review and Meta-Analysis. J Clin Med. 2020; 9.
dc.identifier.citedreferenceTsai SJ, Ding YW, Shih MC, Tu YK. Systematic review and sequential network meta-analysis on the efficacy of periodontal regenerative therapies. J Clin Periodontol. 2020; 47: 1108 - 1120.
dc.identifier.citedreferenceTavelli L, Ravida A, Barootchi S, Chambrone L, Giannobile WV. Recombinant human platelet-derived growth factor: a systematic review of clinical findings in oral regenerative procedures. JDR Clin Trans Res. 2021; 6: 161 - 173.
dc.identifier.citedreferenceCortellini P, Tonetti MS. Clinical and radiographic outcomes of the modified minimally invasive surgical technique with and without regenerative materials: a randomized-controlled trial in intra-bony defects. Journal of Clinical Periodontology. 2011; 38: 365 - 373.
dc.identifier.citedreferenceMeyle J, Hoffmann T, Topoll H, et al. A multi-centre randomized controlled clinical trial on the treatment of intra-bony defects with enamel matrix derivatives/synthetic bone graft or enamel matrix derivatives alone: results after 12 months. J Clin Periodontol. 2011; 38: 652 - 660.
dc.identifier.citedreferenceHiggins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343: d5928.
dc.identifier.citedreferenceBarootchi S, Tavelli L, Zucchelli G, Giannobile WV, Wang HL. Gingival phenotype modification therapies on natural teeth: a network meta-analysis. J Periodontol. 2020; 91: 1386 - 1399.
dc.identifier.citedreferenceTu YK. Linear mixed model approach to network meta-analysis for continuous outcomes in periodontal research. J Clin Periodontol. 2015; 42: 204 - 212.
dc.identifier.citedreferenceCairo F, Barootchi S, Tavelli L, et al. Aesthetic-And patient-related outcomes following root coverage procedures: a systematic review and network meta-analysis. J Clin Periodontol. 2020; 47: 1403 - 1415.
dc.identifier.citedreferenceTavelli L, Barootchi S, Avila-Ortiz G, Urban IA, Giannobile WV, Wang HL. Peri-implant soft tissue phenotype modification and its impact on peri-implant health: a systematic review and network meta-analysis. J Periodontol. 2021; 92: 21 - 44.
dc.identifier.citedreferenceDel Fabbro M, Karanxha L, Panda S, et al. Autologous platelet concentrates for treating periodontal infrabony defects. The Cochrane database of systematic reviews. 2018; 11.
dc.identifier.citedreferenceBurnham PKADR. Model Selection and Multimodel Inference. Springer-Verlag New York; 2002. XXVI, 488.
dc.identifier.citedreferenceBates DMM, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software. 2015; 67: 1 - 48.
dc.identifier.citedreferenceKuznetsova ABPB, Christensen RHB. lmerTest Package: tests in linear mixed effects models. Journal of Statistical Software. 2017; 82: 1 - 26.
dc.identifier.citedreferenceWickham HFR, Henry L, Müller K, dplyr: A Grammar of Data Manipulation. 2019.
dc.identifier.citedreferencewickham HH, L. tidyr: tidy Messy Data. 2019.
dc.identifier.citedreferenceCsardi GN. The igraph software package for complex network research. InterJournal. 2006: 1695. Complex Systems.
dc.identifier.citedreferenceWickham H, ggplot2: Elegant Graphics for Data Analysis. 2016.
dc.identifier.citedreferenceAmerican Dental Association (ADA) Clinical Practice Guidelines Handbook. 2013. Accessed May 1st. http://ebd.ada.org/~/media/EBD/Files/ADA_Clinical_Practice_Guidelines_Handbook-2013.ashx
dc.identifier.citedreferenceMandelaris GA, Neiva R, Chambrone L. Cone-Beam Computed Tomography and Interdisciplinary Dentofacial Therapy: an American Academy of Periodontology Best Evidence Review Focusing on Risk Assessment of the Dentoalveolar Bone Changes Influenced by Tooth Movement. J Periodontol. 2017; 88: 960 - 977.
dc.identifier.citedreferenceChambrone L, Ramos UD, Reynolds MA. Infrared lasers for the treatment of moderate to severe periodontitis: an American Academy of Periodontology best evidence review. J Periodontol. 2018; 89: 743 - 765.
dc.identifier.citedreferenceAbu-Ta’a M. Adjunctive Systemic Antimicrobial Therapy vs Asepsis in Conjunction with Guided Tissue Regeneration: a Randomized, Controlled Clinical Trial. J Contemp Dent Pract. 2016; 17: 3 - 6.
dc.identifier.citedreferenceAgarwal A, Gupta ND. Platelet-rich plasma combined with decalcified freeze-dried bone allograft for the treatment of noncontained human intrabony periodontal defects: a randomized controlled split-mouth study. Int J Periodontics Restorative Dent. 2014; 34: 705 - 711.
dc.identifier.citedreferenceAgarwal A, Gupta ND, Jain A. Platelet rich fibrin combined with decalcified freeze-dried bone allograft for the treatment of human intrabony periodontal defects: a randomized split mouth clinical trail. Acta Odontol Scand. 2016; 74: 36 - 43.
dc.identifier.citedreferenceAgrali ÖB, Kuru BE, Yarat A, Kuru L. Evaluation of gingival crevicular fluid transforming growth factor-β1 level after treatment of intrabony periodontal defects with enamel matrix derivatives and autogenous bone graft: a randomized controlled clinical trial. Niger J Clin Pract. 2016; 19: 535 - 543.
dc.identifier.citedreferenceAgrawal I, Chandran S, Nadig P. Comparative evaluation of the efficacy of platelet-rich fibrin and calcium phosphosilicate putty alone and in combination in the treatment of intrabony defects: a randomized clinical and radiographic study. Contemp Clin Dent. 2017; 8: 205 - 210.
dc.identifier.citedreferenceAhmad N, Tewari S, Narula SC, Sharma RK, Tanwar N. Platelet-rich fibrin along with a modified minimally invasive surgical technique for the treatment of intrabony defects: a randomized clinical trial. J Periodontal Implant Sci. 2019; 49: 355 - 365.
dc.identifier.citedreferenceAimetti M, Ferrarotti F, Mariani GM, Romano F. A novel flapless approach versus minimally invasive surgery in periodontal regeneration with enamel matrix derivative proteins: a 24-month randomized controlled clinical trial. Clin Oral Investig. 2017; 21: 327 - 337.
dc.identifier.citedreferenceAjwani H, Shetty S, Gopalakrishnan D, et al. Comparative evaluation of platelet-rich fibrin biomaterial and open flap debridement in the treatment of two and three wall intrabony defects. J Int Oral Health. 2015; 7: 32 - 37.
dc.identifier.citedreferenceAl Machot E, Hoffmann T, Lorenz K, Khalili I, Noack B. Clinical outcomes after treatment of periodontal intrabony defects with nanocrystalline hydroxyapatite (Ostim) or enamel matrix derivatives (Emdogain): a randomized controlled clinical trial. Biomed Res Int. 2014; 2014: 786353.
dc.identifier.citedreferenceAslan S, Buduneli N, Cortellini P. Clinical outcomes of the entire papilla preservation technique with and without biomaterials in the treatment of isolated intrabony defects: a randomized controlled clinical trial. J Clin Periodontol. 2020; 47: 470 - 478.
dc.identifier.citedreferenceAspriello SD, Ferrante L, Rubini C, Piemontese M. Comparative study of DFDBA in combination with enamel matrix derivative versus DFDBA alone for treatment of periodontal intrabony defects at 12 months post-surgery. Clin Oral Investig. 2011; 15: 225 - 232.
dc.identifier.citedreferenceAtchuta A, Gooty J, Guntakandla V, Palakuru S, Durvasula S, Palaparthy R. Clinical and radiographic evaluation of platelet-rich fibrin as an adjunct to bone grafting demineralized freeze-dried bone allograft in intrabony defects. J Indian Soc Periodontol. 2020; 24: 60 - 66.
dc.identifier.citedreferenceAydemir Turkal H, Demirer S, Dolgun A, Keceli HG. Evaluation of the adjunctive effect of platelet-rich fibrin to enamel matrix derivative in the treatment of intrabony defects. Six-month results of a randomized, split-mouth, controlled clinical study. J Clin Periodontol. 2016; 43: 955 - 964.
dc.identifier.citedreferenceBahammam MA, Attia MS. Expression of Vascular Endothelial Growth Factor Using Platelet Rich Fibrin (PRF) and Nanohydroxyapatite (nano-HA) in Treatment of Periodontal Intra-Bony Defects – A Randomized Controlled Trial. Saudi J Biol Sci. 2021; 28: 870 - 878.
dc.identifier.citedreferenceBansal C, Bharti V. Evaluation of efficacy of autologous platelet-rich fibrin with demineralized-freeze dried bone allograft in the treatment of periodontal intrabony defects. J Indian Soc Periodontol. 2013; 17: 361 - 366.
dc.identifier.citedreferenceBhutda G, Deo V. Five years clinical results following treatment of human intra-bony defects with an enamel matrix derivative: a randomized controlled trial. Acta Odontol Scand. 2013; 71: 764 - 770.
dc.identifier.citedreferenceBodhare GH, Kolte AP, Kolte RA, Shirke PY. Clinical and radiographic evaluation and comparison of bioactive bone alloplast morsels when used alone and in combination with platelet-rich fibrin in the treatment of periodontal intrabony defects-A randomized controlled trial. J Periodontol. 2019; 90: 584 - 594.
dc.identifier.citedreferenceBokan I, Bill JS, Schlagenhauf U. Primary flap closure combined with Emdogain alone or Emdogain and Cerasorb in the treatment of intra-bony defects. J Clin Periodontol. 2006; 33: 885 - 893.
dc.identifier.citedreferenceBratthall G, Lindberg P, Havemose-Poulsen A, et al. Comparison of ready-to-use EMDOGAIN-gel and EMDOGAIN in patients with chronic adult periodontitis. J Clin Periodontol. 2001; 28: 923 - 929.
dc.identifier.citedreferenceCamargo PM, Lekovic V, Weinlaender M, Vasilic N, Kenney EB, Madzarevic M. The effectiveness of enamel matrix proteins used in combination with bovine porous bone mineral in the treatment of intrabony defects in humans. J Clin Periodontol. 2001; 28: 1016 - 1022.
dc.identifier.citedreferenceCamargo PM, Lekovic V, Weinlaender M, Vasilic N, Madzarevic M, Kenney EB. A reentry study on the use of bovine porous bone mineral, GTR, and platelet-rich plasma in the regenerative treatment of intrabony defects in humans. Int J Periodontics Restorative Dent. 2005; 25: 49 - 59.
dc.identifier.citedreferenceChadwick JK, Mills MP, Mealey BL. Clinical and Radiographic Evaluation of Demineralized Freeze-Dried Bone Allograft Versus Platelet-Rich Fibrin for the Treatment of Periodontal Intrabony Defects in Humans. J Periodontol. 2016; 87: 1253 - 1260.
dc.identifier.citedreferenceChambrone D, Pasin IM, Chambrone L, Pannuti CM, Conde MC, Lima LA. Treatment of infrabony defects with or without enamel matrix proteins: a 24-month follow-up randomized pilot study. Quintessence Int. 2010; 41: 125 - 134.
dc.identifier.citedreferenceChambrone D, Pasin IM, Conde MC, Panutti C, Carneiro S, Lima LA. Effect of enamel matrix proteins on the treatment of intrabony defects: a split-mouth randomized controlled trial study. Braz Oral Res. 2007; 21: 241 - 246.
dc.identifier.citedreferenceChandradas ND, Ravindra S, Rangaraju VM, Jain S, Dasappa S. Efficacy of platelet rich fibrin in the treatment of human intrabony defects with or without bone graft: a randomized controlled trial. J Int Soc Prev Community Dent. 2016; 6: S153 - 159.
dc.identifier.citedreferenceChatterjee A, Pradeep AR, Garg V, Yajamanya S, Ali MM, Priya VS. Treatment of periodontal intrabony defects using autologous platelet-rich fibrin and titanium platelet-rich fibrin: a randomized, clinical, comparative study. J Investig Clin Dent. 2017; 8.
dc.identifier.citedreferenceCrea A, Dassatti L, Hoffmann O, Zafiropoulos GG, Deli G. Treatment of intrabony defects using guided tissue regeneration or enamel matrix derivative: a 3-year prospective randomized clinical study. J Periodontol. 2008; 79: 2281 - 2289.
dc.identifier.citedreferenceDe Leonardis D, Paolantonio M. Enamel matrix derivative, alone or associated with a synthetic bone substitute, in the treatment of 1- to 2-wall periodontal defects. J Periodontol. 2013; 84: 444 - 455.
dc.identifier.citedreferenceDemir B, Sengün D, Berberoğlu A. Clinical evaluation of platelet-rich plasma and bioactive glass in the treatment of intra-bony defects. J Clin Periodontol. 2007; 34: 709 - 715.
dc.identifier.citedreferenceDilsiz A, Canakci V, Aydin T. The combined use of Nd: yAG laser and enamel matrix proteins in the treatment of periodontal infrabony defects. J Periodontol. 2010; 81: 1411 - 1418.
dc.identifier.citedreferenceDöri F, Arweiler N, Gera I, Sculean A. Clinical evaluation of an enamel matrix protein derivative combined with either a natural bone mineral or beta-tricalcium phosphate. J Periodontol. 2005; 76: 2236 - 2243.
dc.identifier.citedreferenceDöri F, Arweiler N, Húszár T, Gera I, Miron RJ, Sculean A. Five-year results evaluating the effects of platelet-rich plasma on the healing of intrabony defects treated with enamel matrix derivative and natural bone mineral. J Periodontol. 2013; 84: 1546 - 1555.
dc.identifier.citedreferenceDöri F, Arweiler NB, Szántó E, Agics A, Gera I, Sculean A. Ten-year results following treatment of intrabony defects with an enamel matrix protein derivative combined with either a natural bone mineral or a β-tricalcium phosphate. J Periodontol. 2013; 84: 749 - 757.
dc.identifier.citedreferenceDöri F, Huszár T, Nikolidakis D, Arweiler NB, Gera I, Sculean A. Effect of platelet-rich plasma on the healing of intra-bony defects treated with a natural bone mineral and a collagen membrane. J Clin Periodontol. 2007; 34: 254 - 261.
dc.identifier.citedreferenceDöri F, Kovács V, Arweiler NB, et al. Effect of platelet-rich plasma on the healing of intrabony defects treated with an anorganic bovine bone mineral: a pilot study. J Periodontol. 2009; 80: 1599 - 1605.
dc.identifier.citedreferenceDori F, Nikolidakis D, Huszar T, Arweiler NB, Gera I, Sculean A. Effect of platelet-rich plasma on the healing of intrabony defects treated with an enamel matrix protein derivative and a natural bone mineral. J Clin Periodontol. 2008; 35: 44 - 50.
dc.identifier.citedreferenceElbehwashy MT, Hosny MM, Elfana A, Nawar A. Fawzy El-Sayed K. Clinical and radiographic effects of ascorbic acid-augmented platelet-rich fibrin versus platelet-rich fibrin alone in intra-osseous defects of stage-III periodontitis patients: a randomized controlled clinical trial. Clin Oral Investig. 2021.
dc.identifier.citedreferenceElgendy EA, Abo Shady TE. Clinical and radiographic evaluation of nanocrystalline hydroxyapatite with or without platelet-rich fibrin membrane in the treatment of periodontal intrabony defects. J Indian Soc Periodontol. 2015; 19: 61 - 65.
dc.identifier.citedreferenceFickl S, Thalmair T, Kebschull M, Böhm S, Wachtel H. Microsurgical access flap in conjunction with enamel matrix derivative for the treatment of intra-bony defects: a controlled clinical trial. J Clin Periodontol. 2009; 36: 784 - 790.
dc.identifier.citedreferenceFileto Mazzonetto AL, Casarin RCV, Santamaria MP, et al. Clinical, radiographic, and patient-centered outcomes after use of enamel matrix proteins for the treatment of intrabony defects in patients with aggressive periodontitis: a 12-month multicenter clinical trial. J Periodontol. 2021; 92: 995 - 1006.
dc.identifier.citedreferenceFrancetti L, Del Fabbro M, Basso M, Testori T, Weinstein R. Enamel matrix proteins in the treatment of intra-bony defects. A prospective 24-month clinical trial. J Clin Periodontol. 2004; 31: 52 - 59.
dc.identifier.citedreferenceFrancetti L, Trombelli L, Lombardo G, et al. Evaluation of efficacy of enamel matrix derivative in the treatment of intrabony defects: a 24-month multicenter study. Int J Periodontics Restorative Dent. 2005; 25: 461 - 473.
dc.identifier.citedreferenceFroum SJ, Weinberg MA, Rosenberg E, Tarnow D. A comparative study utilizing open flap debridement with and without enamel matrix derivative in the treatment of periodontal intrabony defects: a 12-month re-entry study. J Periodontol. 2001; 72: 25 - 34.
dc.identifier.citedreferenceGalav S, Chandrashekar KT, Mishra R, Tripathi V, Agarwal R, Galav A. Comparative evaluation of platelet-rich fibrin and autogenous bone graft for the treatment of infrabony defects in chronic periodontitis: clinical, radiological, and surgical reentry. Indian J Dent Res. 2016; 27: 502 - 507.
dc.identifier.citedreferenceGamal AY, Abdel Ghaffar KA, Alghezwy OA. Crevicular fluid growth factors release profile following the use of platelet-rich fibrin and plasma rich growth factors in treating periodontal intrabony defects: a randomized clinical trial. J Periodontol. 2016; 87: 654 - 662.
dc.identifier.citedreferenceGhezzi C, Ferrantino L, Bernardini L, Lencioni M, Masiero S. Minimally Invasive Surgical Technique in Periodontal Regeneration: a Randomized Controlled Clinical Trial Pilot Study. Int J Periodontics Restorative Dent. 2016; 36: 475 - 482.
dc.identifier.citedreferenceGrusovin MG, Esposito M. The efficacy of enamel matrix derivative (Emdogain) for the treatment of deep infrabony periodontal defects: a placebo-controlled randomised clinical trial. Eur J Oral Implantol. 2009; 2: 43 - 54.
dc.identifier.citedreferenceGuida L, Annunziata M, Belardo S, Farina R, Scabbia A, Trombelli L. Effect of autogenous cortical bone particulate in conjunction with enamel matrix derivative in the treatment of periodontal intraosseous defects. J Periodontol. 2007; 78: 231 - 238.
dc.identifier.citedreferenceGupta SJ, Jhingran R, Gupta V, Bains VK, Madan R, Rizvi I. Efficacy of platelet-rich fibrin vs. enamel matrix derivative in the treatment of periodontal intrabony defects: a clinical and cone beam computed tomography study. J Int Acad Periodontol. 2014; 16: 86 - 96.
dc.identifier.citedreferenceGurinsky BS, Mills MP, Mellonig JT. Clinical evaluation of demineralized freeze-dried bone allograft and enamel matrix derivative versus enamel matrix derivative alone for the treatment of periodontal osseous defects in humans. J Periodontol. 2004; 75: 1309 - 1318.
dc.identifier.citedreferenceHanna R, Trejo PM, Weltman RL. Treatment of intrabony defects with bovine-derived xenograft alone and in combination with platelet-rich plasma: a randomized clinical trial. J Periodontol. 2004; 75: 1668 - 1677.
dc.identifier.citedreferenceHarnack L, Boedeker RH, Kurtulus I, Boehm S, Gonzales J, Meyle J. Use of platelet-rich plasma in periodontal surgery–a prospective randomised double blind clinical trial. Clin Oral Investig. 2009; 13: 179 - 187.
dc.identifier.citedreferenceHassan KS, Alagl AS, Abdel-Hady A. Torus mandibularis bone chips combined with platelet rich plasma gel for treatment of intrabony osseous defects: clinical and radiographic evaluation. Int J Oral Maxillofac Surg. 2012; 41: 1519 - 1526.
dc.identifier.citedreferenceHazari V, Choudhary A, Mishra R, Chandrashekar KT, Trivedi A, Pathak PK. Clinical and radiographic analysis of novabone putty with platelet-rich fibrin in the treatment of periodontal intrabony defects: a randomized control trial. Contemp Clin Dent. 2021; 12: 150 - 156.
dc.identifier.citedreferenceHeijl L, Heden G, Svärdström G, Ostgren A. Enamel matrix derivative (EMDOGAIN) in the treatment of intrabony periodontal defects. J Clin Periodontol. 1997; 24: 705 - 714.
dc.identifier.citedreferenceHoffmann T, Al-Machot E, Meyle J, Jervøe-Storm PM, Jepsen S. Three-year results following regenerative periodontal surgery of advanced intrabony defects with enamel matrix derivative alone or combined with a synthetic bone graft. Clin Oral Investig. 2016; 20: 357 - 364.
dc.identifier.citedreferenceHoidal MJ, Grimard BA, Mills MP, Schoolfield JD, Mellonig JT, Mealey BL. Clinical evaluation of demineralized freeze-dried bone allograft with and without enamel matrix derivative for the treatment of periodontal osseous defects in humans. J Periodontol. 2008; 79: 2273 - 2280.
dc.identifier.citedreferenceIlgenli T, Dundar N, Kal BI. Demineralized freeze-dried bone allograft and platelet-rich plasma vs platelet-rich plasma alone in infrabony defects: a clinical and radiographic evaluation. Clin Oral Investig. 2007; 11: 51 - 59.
dc.identifier.citedreferenceIorio Siciliano V, Andreuccetti G, Siciliano AI, Blasi A, Sculean A, Salvi GE. Clinical outcomes after treatment of non-contained intrabony defects with enamel matrix derivative or guided tissue regeneration: a 12-month randomized controlled clinical trial. J Periodontol. 2011; 82: 62 - 71.
dc.identifier.citedreferenceIorio-Siciliano V, Andreuccetti G, Blasi A, Matarasso M, Sculean A, Salvi GE. Clinical outcomes following regenerative therapy of non-contained intrabony defects using a deproteinized bovine bone mineral combined with either enamel matrix derivative or collagen membrane. J Periodontol. 2014; 85: 1342 - 1350.
dc.identifier.citedreferenceJalaluddin M, Mahesh J, Mahesh R, et al. Effectiveness of platelet rich plasma and bone graft in the treatment of intrabony defects: a clinico-radiographic study. Open Dent J. 2018; 12: 133 - 154.
dc.identifier.citedreferenceJalaluddin M, Singh DK, Jayanti I, Kulkarni P, Faizuddin M, Tarannum F. Use of platelet rich plasma in the management of periodontal intra-osseous defects: a clinical study. J Int Soc Prev Community Dent. 2017; 7: 105 - 115.
dc.identifier.citedreferenceJayakumar A, Rajababu P, Rohini S, et al. Multi-centre, randomized clinical trial on the efficacy and safety of recombinant human platelet-derived growth factor with β-tricalcium phosphate in human intra-osseous periodontal defects. J Clin Periodontol. 2011; 38: 163 - 172.
dc.identifier.citedreferenceJepsen S, Topoll H, Rengers H, et al. Clinical outcomes after treatment of intra-bony defects with an EMD/synthetic bone graft or EMD alone: a multicentre randomized-controlled clinical trial. J Clin Periodontol. 2008; 35: 420 - 428.
dc.identifier.citedreferenceKanoriya D, Pradeep AR, Singhal S, Garg V, Guruprasad CN. Synergistic approach using platelet-rich fibrin and 1% alendronate for intrabony defect treatment in chronic periodontitis: a randomized clinical trial. J Periodontol. 2016; 87: 1427 - 1435.
dc.identifier.citedreferenceKaushick BT, Jayakumar ND, Padmalatha O, Varghese S. Treatment of human periodontal infrabony defects with hydroxyapatite + β tricalcium phosphate bone graft alone and in combination with platelet rich plasma: a randomized clinical trial. Indian J Dent Res. 2011; 22: 505 - 510.
dc.identifier.citedreferenceKavyamala D, NVS G, Dwarakanath CD, Anudeep M. Evaluation of the Efficacy of a 1:1 Mixture of beta-TCP and rhPDGF-BB in the Surgical Management of Two- and Three-Wall Intraosseous Defects: a Prospective Clinical Trial. Int J Periodontics Restorative Dent. 2019; 39: 107 - 113.
dc.identifier.citedreferenceKeles GC, Cetinkaya BO, Albayrak D, Koprulu H, Acikgoz G. Comparison of platelet pellet and bioactive glass in periodontal regenerative therapy. Acta Odontol Scand. 2006; 64: 327 - 333.
dc.identifier.citedreferenceKhosropanah H, Shahidi S, Basri A, Houshyar M. Treatment of intrabony defects by DFDBA alone or in combination with PRP: a split-mouth randomized clinical and three-dimensional radiographic trial. J Dent (Tehran). 2015; 12: 764 - 773.
dc.identifier.citedreferenceKitamura M, Akamatsu M, Kawanami M, et al. Randomized placebo-controlled and controlled non-inferiority phase IIi trials comparing trafermin, a recombinant human fibroblast growth factor 2, and enamel matrix derivative in periodontal regeneration in intrabony defects. J Bone Miner Res. 2016; 31: 806 - 814.
dc.identifier.citedreferenceKuru B, Yilmaz S, Argin K, Noyan U. Enamel matrix derivative alone or in combination with a bioactive glass in wide intrabony defects. Clin Oral Investig. 2006; 10: 227 - 234.
dc.identifier.citedreferenceLee JH, Kim DH, Jeong SN. Adjunctive use of enamel matrix derivatives to porcine-derived xenograft for the treatment of one-wall intrabony defects: two-year longitudinal results of a randomized controlled clinical trial. J Periodontol. 2020; 91: 880 - 889.
dc.identifier.citedreferenceLee JY, Na HJ, Kim HM, et al. Comparative Study of rhPDGF-BB Plus Equine-Derived Bone Matrix Versus rhPDGF-BB Plus β-TCP in the Treatment of Periodontal Defects. Int J Periodontics Restorative Dent. 2017; 37: 825 - 832.
dc.identifier.citedreferenceLeknes KN, Andersen KM, Bøe OE, Skavland RJ, Albandar JM. Enamel matrix derivative versus bioactive ceramic filler in the treatment of intrabony defects: 12-month results. J Periodontol. 2009; 80: 219 - 227.
dc.identifier.citedreferenceLekovic V, Camargo PM, Weinlaender M, Nedic M, Aleksic Z, Kenney EB. A comparison between enamel matrix proteins used alone or in combination with bovine porous bone mineral in the treatment of intrabony periodontal defects in humans. J Periodontol. 2000; 71: 1110 - 1116.
dc.identifier.citedreferenceLekovic V, Camargo PM, Weinlaender M, Vasilic N, Djordjevic M, Kenney EB. The use of bovine porous bone mineral in combination with enamel matrix proteins or with an autologous fibrinogen/fibronectin system in the treatment of intrabony periodontal defects in humans. J Periodontol. 2001; 72: 1157 - 1163.
dc.identifier.citedreferenceLekovic V, Camargo PM, Weinlaender M, Vasilic N, Kenney EB. Comparison of platelet-rich plasma, bovine porous bone mineral, and guided tissue regeneration versus platelet-rich plasma and bovine porous bone mineral in the treatment of intrabony defects: a reentry study. J Periodontol. 2002; 73: 198 - 205.
dc.identifier.citedreferenceLekovic V, Milinkovic I, Aleksic Z, et al. Platelet-rich fibrin and bovine porous bone mineral vs. platelet-rich fibrin in the treatment of intrabony periodontal defects. J Periodontal Res. 2012; 47: 409 - 417.
dc.identifier.citedreferenceLiu K, Huang Z, Chen Z, Han B, Ouyang X. Treatment of periodontal intrabony defects using bovine porous bone mineral and guided tissue regeneration with/without platelet-rich fibrin: a randomized controlled clinical trial. J Periodontol. 2021.
dc.identifier.citedreferenceLosada M, González R, Garcia À, Santos A, Nart J. Treatment of Non-Contained Infrabony Defects With Enamel Matrix Derivative Alone or in Combination With Biphasic Calcium Phosphate Bone Graft: a 12-Month Randomized Controlled Clinical Trial. J Periodontol. 2017; 88: 426 - 435.
dc.identifier.citedreferenceMarkou N, Pepelassi E, Vavouraki H, et al. Treatment of periodontal endosseous defects with platelet-rich plasma alone or in combination with demineralized freeze-dried bone allograft: a comparative clinical trial. J Periodontol. 2009; 80: 1911 - 1919.
dc.identifier.citedreferenceMaroo S, Murthy KR. Treatment of periodontal intrabony defects using β-TCP alone or in combination with rhPDGF-BB: a randomized controlled clinical and radiographic study. Int J Periodontics Restorative Dent. 2014; 34: 841 - 847.
dc.identifier.citedreferenceMartande SS, Kumari M, Pradeep AR, Singh SP, Suke DK, Guruprasad CN. Platelet-rich fibrin combined with 1.2% atorvastatin for treatment of intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2016; 87: 1039 - 1046.
dc.identifier.citedreferenceMathur A, Bains VK, Gupta V, Jhingran R, Singh GP. Evaluation of intrabony defects treated with platelet-rich fibrin or autogenous bone graft: a comparative analysis. Eur J Dent. 2015; 9: 100 - 108.
dc.identifier.citedreferenceMinabe M, Kodama T, Kogou T, et al. A comparative study of combined treatment with a collagen membrane and enamel matrix proteins for the regeneration of intraosseous defects. Int J Periodontics Restorative Dent. 2002; 22: 595 - 605.
dc.identifier.citedreferenceMishra A, Avula H, Pathakota KR, Avula J. Efficacy of modified minimally invasive surgical technique in the treatment of human intrabony defects with or without use of rhPDGF-BB gel: a randomized controlled trial. J Clin Periodontol. 2013; 40: 172 - 179.
dc.identifier.citedreferenceMoreno Rodriguez JA, Ortiz Ruiz AJ. Apical approach in periodontal reconstructive surgery with enamel matrix derivate and enamel matrix derivate plus bone substitutes: a randomized, controlled clinical trial. Clin Oral Investig. 2021.
dc.identifier.citedreferenceNaqvi A, Gopalakrishnan D, Bhasin MT, Sharma N, Haider K, Martande S. Comparative Evaluation of Bioactive Glass Putty and Platelet Rich Fibrin in the Treatment of Human Periodontal Intrabony Defects: a Randomized Control Trial. J Clin Diagn Res. 2017; 11: Zc09 - zc13.
dc.identifier.citedreferenceNevins M, Kao RT, McGuire MK, et al. Platelet-derived growth factor promotes periodontal regeneration in localized osseous defects: 36-month extension results from a randomized, controlled, double-masked clinical trial. J Periodontol. 2013; 84: 456 - 464.
dc.identifier.citedreferenceOgihara S, Tarnow DP. Efficacy of enamel matrix derivative with freeze-dried bone allograft or demineralized freeze-dried bone allograft in intrabony defects: a randomized trial. J Periodontol. 2014; 85: 1351 - 1360.
dc.identifier.citedreferenceOgihara S, Wang HL. Periodontal regeneration with or without limited orthodontics for the treatment of 2- or 3-wall infrabony defects. J Periodontol. 2010; 81: 1734 - 1742.
dc.identifier.citedreferenceOkuda K, Tai H, Tanabe K, et al. Platelet-rich plasma combined with a porous hydroxyapatite graft for the treatment of intrabony periodontal defects in humans: a comparative controlled clinical study. J Periodontol. 2005; 76: 890 - 898.
dc.identifier.citedreferenceOzcelik O, Cenk Haytac M, Seydaoglu G. Enamel matrix derivative and low-level laser therapy in the treatment of intra-bony defects: a randomized placebo-controlled clinical trial. J Clin Periodontol. 2008; 35: 147 - 156.
dc.identifier.citedreferenceOzdemir B, Okte E. Treatment of intrabony defects with beta-tricalciumphosphate alone and in combination with platelet-rich plasma. J Biomed Mater Res B Appl Biomater. 2012; 100: 976 - 983.
dc.identifier.citedreferencePanda S, Sankari M, Satpathy A, et al. Adjunctive Effect of Autologus Platelet-Rich Fibrin to Barrier Membrane in the Treatment of Periodontal Intrabony Defects. J Craniofac Surg. 2016; 27: 691 - 696.
dc.identifier.citedreferencePatel GK, Gaekwad SS, Gujjari SK, CV S. Platelet-Rich Fibrin in Regeneration of Intrabony Defects: a Randomized Controlled Trial. J Periodontol. 2017; 88: 1192 - 1199.
dc.identifier.citedreferencePavani MP, Reddy K, Reddy BH, Biraggari SK, Babu CHC, Chavan V. Evaluation of platelet-rich fibrin and tricalcium phosphate bone graft in bone fill of intrabony defects using cone-beam computed tomography: a randomized clinical trial. J Indian Soc Periodontol. 2021; 25: 138 - 143.
dc.identifier.citedreferencePham TAV. Intrabony defect treatment with platelet-rich fibrin, guided tissue regeneration and open-flap debridement: a randomized controlled trial. J Evid Based Dent Pract. 2021; 21: 101545.
dc.identifier.citedreferencePiemontese M, Aspriello SD, Rubini C, Ferrante L, Procaccini M. Treatment of periodontal intrabony defects with demineralized freeze-dried bone allograft in combination with platelet-rich plasma: a comparative clinical trial. J Periodontol. 2008; 79: 802 - 810.
dc.identifier.citedreferencePietruska M, Pietruski J, Nagy K, Brecx M, Arweiler NB, Sculean A. Four-year results following treatment of intrabony periodontal defects with an enamel matrix derivative alone or combined with a biphasic calcium phosphate. Clin Oral Investig. 2012; 16: 1191 - 1197.
dc.identifier.citedreferencePilloni A, Rojas MA, Marini L, et al. Healing of intrabony defects following regenerative surgery by means of single-flap approach in conjunction with either hyaluronic acid or an enamel matrix derivative: a 24-month randomized controlled clinical trial. Clin Oral Investig. 2021; 25: 5095 - 5107.
dc.identifier.citedreferencePontoriero R, Wennstrom J, Lindhe J. The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. A prospective controlled clinical study. J Clin Periodontol. 1999; 26: 833 - 840.
dc.identifier.citedreferencePradeep AR, Bajaj P, Rao NS, Agarwal E, Naik SB. Platelet-rich fibrin combined with a porous hydroxyapatite graft for the treatment of 3-wall intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2017; 88: 1288 - 1296.
dc.identifier.citedreferencePradeep AR, Garg V, Kanoriya D, Singhal S. Platelet-Rich Fibrin With 1.2% Rosuvastatin for Treatment of Intrabony Defects in Chronic Periodontitis: a Randomized Controlled Clinical Trial. J Periodontol. 2016; 87: 1468 - 1473.
dc.identifier.citedreferencePradeep AR, Nagpal K, Karvekar S, Patnaik K, Naik SB, Guruprasad CN. Platelet-rich fibrin with 1% metformin for the treatment of intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2015; 86: 729 - 737.
dc.identifier.citedreferencePradeep AR, Shetty SK, Garg G, Pai S. Clinical effectiveness of autologous platelet-rich plasma and Peptide-enhanced bone graft in the treatment of intrabony defects. J Periodontol. 2009; 80: 62 - 71.
dc.identifier.citedreferenceRagghianti Zangrando MS, Chambrone D, Pasin IM, Conde MC, Pannuti CM, de Lima LA. Two-year randomized clinical trial of enamel matrix derivative treated infrabony defects: radiographic analysis. BMC oral health. 2014; 14: 149.
dc.identifier.citedreferenceRavi S, Malaiappan S, Varghese S, Jayakumar ND, Prakasam G. Additive effect of plasma rich in growth factors with guided tissue regeneration in treatment of intrabony defects in patients with chronic periodontitis: a split-mouth randomized controlled clinical trial. J Periodontol. 2017; 88: 839 - 845.
dc.identifier.citedreferenceRibeiro FV, Casarin RC, Júnior FH, Sallum EA, Casati MZ. The role of enamel matrix derivative protein in minimally invasive surgery in treating intrabony defects in single-rooted teeth: a randomized clinical trial. J Periodontol. 2011; 82: 522 - 532.
dc.identifier.citedreferenceRösing CK, Aass AM, Mavropoulos A, Gjermo P. Clinical and radiographic effects of enamel matrix derivative in the treatment of intrabony periodontal defects: a 12-month longitudinal placebo-controlled clinical trial in adult periodontitis patients. J Periodontol. 2005; 76: 129 - 133.
dc.identifier.citedreferenceSaini N, Sikri P, Gupta H. Evaluation of the relative efficacy of autologous platelet-rich plasma in combination with β-tricalcium phosphate alloplast versus an alloplast alone in the treatment of human periodontal infrabony defects: a clinical and radiological study. Indian J dent Res. 2011; 22: 107 - 115.
dc.identifier.citedreferenceScheyer ET, Velasquez-Plata D, Brunsvold MA, Lasho DJ, Mellonig JT. A clinical comparison of a bovine-derived xenograft used alone and in combination with enamel matrix derivative for the treatment of periodontal osseous defects in humans. J Periodontol. 2002; 73: 423 - 432.
dc.identifier.citedreferenceSchincaglia GP, Hebert E, Farina R, Simonelli A, Trombelli L. Single versus double flap approach in periodontal regenerative treatment. J Clin Periodontol. 2015; 42: 557 - 566.
dc.identifier.citedreferenceSchwarz F, Sculean A, Georg T, Becker J. Clinical evaluation of the Er: yAG laser in combination with an enamel matrix protein derivative for the treatment of intrabony periodontal defects: a pilot study. J Clin Periodontol. 2003; 30: 975 - 981.
dc.identifier.citedreferenceSculean A, Barbé G, Chiantella GC, Arweiler NB, Berakdar M, Brecx M. Clinical evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. J Periodontol. 2002; 73: 401 - 408.
dc.identifier.citedreferenceSculean A, Berakdar M, Donos N, Auschill TM, Arweiler NB. The effect of postsurgical administration of a selective cyclo-oxygenase-2 inhibitor on the healing of intrabony defects following treatment with enamel matrix proteins. Clin Oral Investig. 2003; 7: 108 - 112.
dc.identifier.citedreferenceSculean A, Berakdar M, Willershausen B, Arweiler NB, Becker J, Schwarz F. Effect of EDTA root conditioning on the healing of intrabony defects treated with an enamel matrix protein derivative. J Periodontol. 2006; 77: 1167 - 1172.
dc.identifier.citedreferenceSculean A, Blaes A, Arweiler N, Reich E, Donos N, Brecx M. The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins. J Periodontol. 2001; 72: 190 - 195.
dc.identifier.citedreferenceSculean A, Chiantella GC, Windisch P, Gera I, Reich E. Clinical evaluation of an enamel matrix protein derivative (Emdogain) combined with a bovine-derived xenograft (Bio-Oss) for the treatment of intrabony periodontal defects in humans. Int J Periodontics Restorative Dent. 2002; 22: 259 - 267.
dc.identifier.citedreferenceSculean A, Donos N, Blaes A, Lauermann M, Reich E, Brecx M. Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony periodontal defects. A split-mouth study. J Periodontol. 1999; 70: 255 - 262.
dc.identifier.citedreferenceSculean A, Donos N, Miliauskaite A, Arweiler N, Brecx M. Treatment of intrabony defects with enamel matrix proteins or bioabsorbable membranes. A 4-year follow-up split-mouth study. J Periodontol. 2001; 72: 1695 - 1701.
dc.identifier.citedreferenceSculean A, Donos N, Schwarz F, Becker J, Brecx M, Arweiler NB. Five-year results following treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol. 2004; 31: 545 - 549.
dc.identifier.citedreferenceSculean A, Kiss A, Miliauskaite A, Schwarz F, Arweiler NB, Hannig M. Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol. 2008; 35: 817 - 824.
dc.identifier.citedreferenceSculean A, Pietruska M, Arweiler NB, Auschill TM, Nemcovsky C. Four-year results of a prospective-controlled clinical study evaluating healing of intra-bony defects following treatment with an enamel matrix protein derivative alone or combined with a bioactive glass. J Clin Periodontol. 2007; 34: 507 - 513.
dc.identifier.citedreferenceSculean A, Pietruska M, Schwarz F, Willershausen B, Arweiler NB, Auschill TM. Healing of human intrabony defects following regenerative periodontal therapy with an enamel matrix protein derivative alone or combined with a bioactive glass. A controlled clinical study. J Clin Periodontol. 2005; 32: 111 - 117.
dc.identifier.citedreferenceSculean A, Schwarz F, Miliauskaite A, et al. Treatment of intrabony defects with an enamel matrix protein derivative or bioabsorbable membrane: an 8-year follow-up split-mouth study. J Periodontol. 2006; 77: 1879 - 1886.
dc.identifier.citedreferenceSculean A, Windisch P, Chiantella GC, Donos N, Brecx M, Reich E. Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. A prospective controlled clinical study. J Clin Periodontol. 2001; 28: 397 - 403.
dc.identifier.citedreferenceSezgin Y, Uraz A, Taner IL, Çulhaoğlu R. Effects of platelet-rich fibrin on healing of intra-bony defects treated with anorganic bovine bone mineral. Braz Oral Res. 2017; 31: e15.
dc.identifier.citedreferenceShah M, Patel J, Dave D, Shah S. Comparative evaluation of platelet-rich fibrin with demineralized freeze-dried bone allograft in periodontal infrabony defects: a randomized controlled clinical study. J Indian Soc Periodontol. 2015; 19: 56 - 60.
dc.identifier.citedreferenceSharma A, Pradeep AR. Treatment of 3-wall intrabony defects in patients with chronic periodontitis with autologous platelet-rich fibrin: a randomized controlled clinical trial. J Periodontol. 2011; 82: 1705 - 1712.
dc.identifier.citedreferenceShukla S, Chug A, Mahesh L, Grover HS. Effect of Addition of Platelet-rich Plasma to Calcium Phosphosilicate Putty on Healing at 9 Months in Periodontal Intrabony Defects. J Contemp Dent Pract. 2016; 17: 230 - 234.
dc.identifier.citedreferenceSilvestri M, Ricci G, Rasperini G, Sartori S, Cattaneo V. Comparison of treatments of infrabony defects with enamel matrix derivative, guided tissue regeneration with a nonresorbable membrane and Widman modified flap. A pilot study. J Clin Periodontol. 2000; 27: 603 - 610.
dc.identifier.citedreferenceSilvestri M, Sartori S, Rasperini G, Ricci G, Rota C, Cattaneo V. Comparison of infrabony defects treated with enamel matrix derivative versus guided tissue regeneration with a nonresorbable membrane. J Clin Periodontol. 2003; 30: 386 - 393.
dc.identifier.citedreferenceSipos PM, Loos BG, Abbas F, Timmerman MF, van der Velden U. The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects. J Clin Periodontol. 2005; 32: 765 - 772.
dc.identifier.citedreferenceThorat M, Baghele ON, RP S. Adjunctive Effect of Autologous Platelet-Rich Fibrin in the Treatment of Intrabony Defects in Localized Aggressive Periodontitis Patients: a Randomized Controlled Split-Mouth Clinical Trial. Int J Periodontics Restorative Dent. 2017; 37: e302.
dc.identifier.citedreferenceThorat M, Pradeep AR, Pallavi B. Clinical effect of autologous platelet-rich fibrin in the treatment of intra-bony defects: a controlled clinical trial. J Clin Periodontol. 2011; 38: 925 - 932.
dc.identifier.citedreferenceTonetti MS, Fourmousis I, Suvan J, Cortellini P, Brägger U, Lang NP. Healing, post-operative morbidity and patient perception of outcomes following regenerative therapy of deep intrabony defects. J Clin Periodontol. 2004; 31: 1092 - 1098.
dc.identifier.citedreferenceVelasquez-Plata D, Scheyer ET, Mellonig JT. Clinical comparison of an enamel matrix derivative used alone or in combination with a bovine-derived xenograft for the treatment of periodontal osseous defects in humans. J Periodontol. 2002; 73: 433 - 440.
dc.identifier.citedreferenceWindisch P, Iorio-Siciliano V, Palkovics D, Ramaglia L, Blasi A, Sculean A. The role of surgical flap design (minimally invasive flap vs. extended flap with papilla preservation) on the healing of intrabony defects treated with an enamel matrix derivative: a 12-month two-center randomized controlled clinical trial. Clin Oral Investig. 2021.
dc.identifier.citedreferenceYamamiya K, Okuda K, Kawase T, Hata K, Wolff LF, Yoshie H. Tissue-engineered cultured periosteum used with platelet-rich plasma and hydroxyapatite in treating human osseous defects. J Periodontol. 2008; 79: 811 - 818.
dc.identifier.citedreferenceYilmaz S, Cakar G, Yildirim B, Sculean A. Healing of two and three wall intrabony periodontal defects following treatment with an enamel matrix derivative combined with autogenous bone. J Clin Periodontol. 2010; 37: 544 - 550.
dc.identifier.citedreferenceZetterström O, Andersson C, Eriksson L, et al. Clinical safety of enamel matrix derivative (EMDOGAIN) in the treatment of periodontal defects. J Clin Periodontol. 1997; 24: 697 - 704.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jper10959.pdf
Size:
1.026MB
Format:
PDF
View/Open
Name:
jper10959_am.pdf
Size:
1.601MB
Format:
PDF
View/Open
Name:
jper10959-sup-0001-SuppMat.pdf
Size:
1.307MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.